METiS TechBio moves into Nexxus Building
Analysis based on 6 articles · First reported Aug 19, 2026 · Last updated Aug 20, 2026
The lease signals continued recovery in China — Hong Kong's core commercial leasing market and validates Trivium's asset enhancement strategy, potentially boosting occupancy and rental income at Hong Kong — Nexxus Building. For METiS Therapeutics, establishing a presence in Central supports its expansion and may enhance its corporate profile, though the direct financial impact is modest.
On 20 August 2026, METiS Therapeutics, the world's first listed AI-powered drug delivery biotechnology company, officially moved into Hong Kong — Nexxus Building in Central, China — Hong Kong. The move follows Trivium Asset Management's takeover of the building's operations and management earlier in the year, during which it upgraded the 23rd floor into an event space called 'Nexxus Hub' and subdivided the 6th floor into six flexible units. METiS Therapeutics, listed on the Hong Kong Stock Exchange in May 2026, will establish its China — Hong Kong base at the building. Trivium's Managing Partner Wilfred Ma welcomed the tenant, highlighting the building's prime location and quality facilities. The building, built in 1962 as the former headquarters of Hang Seng Bank, continues to attract multinational corporations and financial institutions.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard